Abstract:Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: STAT3 has emerged as a novel potential anti-cancer target and its signaling is constitutively activated in various cancers including breast cancer. Our previous study has shown that STAT3 is a major kinase-independent target of sorafenib in HCC. (J Hepatol. 2011). We have designed and synthesized a series of sorafenib analogues devoid of sorafenib's kinase inhibition activity, some of which showed stronger p-STAT3 inhibition and apoptosis-inducing effects than sorafenib in HCC cells (Eur J Med Chem. 2011). In addition, a protein tyrosine phosphatase SHP-1 has been demonstrated to downregulate p-STAT3 via its phosphatase activity. Here, we tested the efficacy of two sorafenib analogues, SC-1 and SC-43, in breast cancer cells and examined the drug mechanism. Methods: breast cancer cell lines were used for in vitro studies. Apoptosis was examined by both flow cytometry and Western blot. Signal transduction pathways in cells were assessed by Western Blot. Tyrosine Phosphatase Assay Kit was used for SHP-1 activity assay. Gene silencing was done by small interference RNA (siRNA). In vivo efficacy of Sorafenib, and SC-1 and SC-43 were tested in xenografted nude mice. Results: SC-1 and SC-43 induced more potent apoptosis than sorafenib, in association with downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines (HCC-1937, MDA MB-468, MDA MB-231, MDA MB-453, SKBR-3, MCF-7). Overexpression of STAT3 in MDA MB-468 cells protected cells from apoptosis induced by sorafenib, SC-1, and SC-43. Moreover, SC-1 and SC-43 upregulated SHP-1 activity to a greater extent than sorafenib as measured by in vitro phosphatase assays. Knockdown of SHP-1 by siRNA reduced apoptosis induced by SC-1 and SC-43. Importantly, SC-1 and SC-43 showed more efficacious antitumor activity and p-STAT3 downregulation than sorafenib in MDA-468 xenograft tumors. These data indicated that inhibiton of p-STAT3 by up-regulating SHP-1 activity mediated apoptotic effects of SC-1 and SC-43 in breast cancer cells. Moreover, a representative breast tumor tissue demonstrated reciprocal expression of SHP-1 and p-STAT3 in cancer cells and adjacent non-cancer breast tissue. Conclusions: Novel sorafenib analogues SC-1 and SC-43 induce apoptosis through SHP-1 dependent STAT3 inactivation and demonstrate greater potency than sorafenib in human breast cancer cells. (Supported by Yen Tjing Ling Medical Foundation; NSC 101-2325-B-075-006 and NSC 100-2325-B-010-007; VN101-03 (TVGH-NTUH Joint Research Program), V99-B1-016, and V100-D-005-4) Citation Format: Chun-Yu Liu, Ling-Ming Tseng, Kung-Chi Chang, Pei-Yi Chu, Jung-Chen Su, Wei-Tien Tai, Chung-Wai Shiau, Kuen-Feng Chen. Sorafenib analogues SC-1 and SC-43 show better apoptotic effects than sorafenib through SHP-1 dependent STAT3 inhibition in breast cancer cells . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3250. doi:10.1158/1538-7445.AM2013-3250

Phosphorylated Stat3 In Polymorphonucleur Cells (Pmns) As A Potential Surrogate Marker To Evaluate The Efficiency Of Sorafenib Therapy

Abstract 3250: Sorafenib analogues SC-1 and SC-43 show better apoptotic effects than sorafenib through SHP-1 dependent STAT3 inhibition in breast cancer cells .

Coordinative Activities of STAT3 Inhibitor BP-1-102 and Sorafenib Against Proliferation, Angiogenesis and EMT in Hepatocellular Carcinoma

Abstract 3844: A Novel Sorafenib-Derivative SC-1 Induces Apoptosis in Breast Cancer Cells Through STAT3 Inhibition

Phosphorylated ERK is a Potential Prognostic Biomarker for Sorafenib Response in Hepatocellular Carcinoma.

Sorafenib with ASC-J9® Synergistically Suppresses the HCC Progression Via Altering the Pstat3-Ccl2/bcl2 Signals.

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

Abstract 1636: Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib

An Investigation of the Effect of Sorafenib on Tumour Growth and Recurrence after Liver Cancer Resection in Nude Mice Independent of Phosphorylated Extracellular Signal-Regulated Kinase Levels

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Study on the molecular mechanisms of sorafenib inhibiting human peripheral blood T cells

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells

Suppression of the expression of multidrug resistance protein in liver cancer cells by sorafenib and the growth of subcutaneous tumor in nude mice model treated by a combination of sorafenib and fluorouracil

Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.

Abstract 4145: Increased Anti-Tumor Effect of Sorafenib by Depleting Tumor Associated Macrophages

Yc-1 Enhances the Anti-Tumor Activity of Sorafenib Through Inhibition of Signal Transducer and Activator of Transcription 3 (stat3) in Hepatocellular Carcinoma